近期RNA疗法交易热度攀升!艾伯维、礼来、靖因药业接连达成合作

医药经济报
21 May

靖因药业就长效siRNA新药达成授权合作5月20日,靖因药业与CRISPR Therapeutics宣布双方达成战略合作伙伴关系,将携手推进siRNA疗法的联合开发与商业化进程。新闻稿表示,该合作将双方在研发与产业化方面的互补能力相结合,共同开发并商业化下一代长效Factor XI(FXI)靶向小干扰RNA(siRNA)疗法SRSD107,用于治疗血栓及血栓栓塞性疾病。根据协议条款,靖因药业将获得...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10